China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Qinhuangdao Zizhu received the World Health Organization prequalification certificate for its levonorgestrel active pharmaceutical ingredient.
Levonorgestrel is a fast-acting contraceptive drug, according to a Thursday filing with the Shanghai bourse.
The certification confirms the API meets WHO quality standards, providing a key entry qualification for international procurement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.